U.S. Medicare plans to track CAR-T cancer therapy outcomes

The U.S. Centers for Medicare & Medicaid Services (CMS) on Friday proposed coverage of expensive CAR-T cell therapies at cancer centers that meet criteria including an approved registry of patient results or clinical study to monitor patients for at least two years after treatment.